2009/10/14 by T. Fredriksson, T Fredriksson, U. Pettersson · 1 citation
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Biotin and Related Studies #Psoriasis: Treatment and Pathogenesis #Retinoids in leukemia and cellular processes
paper · doi:10.1159/000250839
crossref issued 2009/10/14 · crossref published 2009/10/14 · crossref published-online 2009/10/14 · openalex publication_date 2009/10/14 · crossref created 2009/10/14 · openalex created_date 2025/10/10 · crossref deposited 2026/04/30 · openalex updated_date 2026/07/25 · crossref indexed 2026/08/04
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10--9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.